Nurse-led medicines' monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for mental health medicines: An observational and interview study

Sue Jordan, Timothy Banner, Marie Gabe-Walters, Jane M Mikhail, Gerwyn Panes, Jeff Round, Sherrill Snelgrove, Mel Storey, David Hughes, Medicines’ Management Group, Swansea University, Sue Jordan, Timothy Banner, Marie Gabe-Walters, Jane M Mikhail, Gerwyn Panes, Jeff Round, Sherrill Snelgrove, Mel Storey, David Hughes, Medicines’ Management Group, Swansea University

Abstract

Introduction: Preventable adverse effects of medicines often pass unnoticed, but lead to real harm.

Intervention: Nurse-led monitoring using the structured Adverse Drug Reaction (ADRe) Profile identifies and addresses adverse effects of mental health medicines.

Objectives: This study investigated the implementation and clinical impact of ADRe, and barriers to and facilitators of sustained utilisation in routine practice.

Methods: Administration of ADRe was observed for 30 residents prescribed mental health medicines in ten care homes. The study pharmacist reviewed completed ADRes against medication records. Policy context was explored in 30 interviews with service users, nurse managers and strategic leads in Wales.

Results: Residents were aged 60-95, and prescribed 1-17 (median 9 [interquartile range (IQR) 7-13]) medicines. ADRe identified a median of 18 [IQR 11.5-23] problems per resident and nurses made 2 [1-2] changes to care per resident. For example: falls were reported for 9 residents, and care was modified for 5; pain was identified in 8 residents, and alleviated for 7; all 6 residents recognised as dyspnoeic were referred to prescribers. Nurses referred 17 of 30 residents to prescribers. Pharmacists recommended review for all 30. Doubts about administering ADRe, sometimes expressed by people who had not yet used it, diminished as it became familiar. ADRe was needed to bridge communication between resident, nurses and prescribers. When barriers of time, complacency, and doctors' non-availability were overcome, reporting with ADRe made prescribers more likely to heed nurses' concerns regarding residents' welfare. Clinical gains were facilitated by one-to-one time, staff-resident relationships, and unification of documentation.

Implications: To our knowledge, ADRe is the only instrument that brings a full account of patients' problems to medication reviews. This juxtaposition of signs and symptoms against prescriptions facilitates dose adjustments and de-prescribing and leads to: reduced pain and sedation; early identification of problems linked to ADRs, such as falls; and timely medication reviews e.g. for dyspnoea.

Trial registration: ClinicalTrials.gov NCT03110471.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Participant flow diagram.
Fig 1. Participant flow diagram.
Fig 2. Energy and the ADRe profile.
Fig 2. Energy and the ADRe profile.
All things are difficult before they are easy, Thomas Fuller 1732. Fuller, T. (1732) Gnomologia: Adages and Proverbs, Wise Sentences and Witty Sayings, Collected by Thomas Fuller, No. 560, p.21. London: Barker/Bettesworth and Hitch. Available at: https://books.google.co.uk/books?id=3y8JAAAAQAAJ&printsec=frontcover#v=onepage&q&f=false.
Fig 3. Integrating ADRe into multidisciplinary teams.
Fig 3. Integrating ADRe into multidisciplinary teams.

References

    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9. Epub 2004/07/03. 10.1136/bmj.329.7456.15 .
    1. National Institute for Health and Care Excellence. Medicines optimisation:the safe and effective use of medicines to enable the best possible outcomes. NICE guideline 5 2015 [Accessed 07 April 2019]. .
    1. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017–25. Epub 2008/07/03. 10.1345/aph.1L037 .
    1. Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73(6):759–70. Epub 2017/03/03. 10.1007/s00228-017-2225-3 .
    1. Parameswaran Nair N, Chalmers L, Connolly M, Bereznicki BJ, Peterson GM, Curtain C, et al. Prediction of Hospitalization due to Adverse Drug Reactions in Elderly Community-Dwelling Patients (The PADR-EC Score). PLoS One. 2016;11(10):e0165757 Epub 2016/11/01. 10.1371/journal.pone.0165757 .
    1. Frontier Economic. Exploring the costs of unsafe care in the NHS: a report prepared for The Department of Health 2014 [Accessed 07 April 2019]. .
    1. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079–86. Epub 2014/12/10. 10.2147/CIA.S71178 .
    1. Roulet L, Ballereau F, Hardouin JB, Chiffoleau A, Potel G, Asseray N. Adverse drug event nonrecognition in emergency departments: an exploratory study on factors related to patients and drugs. J Emerg Med. 2014;46(6):857–64. Epub 2014/02/26. 10.1016/j.jemermed.2013.11.124 .
    1. Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. British journal of clinical pharmacology. 2017;83(2):416–26. Epub 2016/09/11. 10.1111/bcp.13124 .
    1. El Morabet N, Uitvlugt EB, van den Bemt BJF, van den Bemt PMLA, Janssen MJA, Karapinar-Çarkit F. Prevalence and Preventability of Drug-Related Hospital Readmissions: A Systematic Review. Journal of the American Geriatrics Society. 2018;66(3):602–8. 10.1111/jgs.15244
    1. Du Y, Wolf IK, Busch MA, Knopf H. Associations between the use of specific psychotropic drugs and all-cause mortality among older adults in Germany: Results of the mortality follow-up of the German National Health Interview and Examination Survey 1998. PLoS One. 2019;14(1):e0210695 Epub 2019/01/15. 10.1371/journal.pone.0210695 .
    1. Avery AJ, Bell BG. Rationalising medications through deprescribing. BMJ. 2019;364:l570 Epub 2019/02/09. 10.1136/bmj.l570 .
    1. Hakkarainen KM, Andersson Sundell K, Petzold M, Hagg S. Prevalence and perceived preventability of self-reported adverse drug events—a population-based survey of 7099 adults. PLoS One. 2013;8(9):e73166 Epub 2013/09/12. 10.1371/journal.pone.0073166 .
    1. Gabe ME, Davies GA, Murphy F, Davies M, Johnstone L, Jordan S. Adverse drug reactions: treatment burdens and nurse-led medication monitoring. Journal of Nursing Management. 2011;19(3):377–92. 10.1111/j.1365-2834.2011.01204.x
    1. Brenner S, Detz A, Lopez A, Horton C, Sarkar U. Signal and noise: applying a laboratory trigger tool to identify adverse drug events among primary care patients. BMJ Qual Saf. 2012;21(8):670–5. Epub 2012/05/26. 10.1136/bmjqs-2011-000643 .
    1. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events occurring following hospital discharge. J Gen Intern Med. 2005;20(4):317–23. Epub 2005/04/29. 10.1111/j.1525-1497.2005.30390.x .
    1. Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118(3):251–8. Epub 2005/03/05. 10.1016/j.amjmed.2004.09.018 .
    1. Steinman MA, Handler SM, Gurwitz JH, Schiff GD, Covinsky KE. Beyond the prescription: medication monitoring and adverse drug events in older adults. J Am Geriatr Soc. 2011;59(8):1513–20. Epub 2011/07/30. 10.1111/j.1532-5415.2011.03500.x .
    1. Gandhi TK, Seger AC, Overhage JM, Murray MD, Hope C, Fiskio J, et al. Outpatient adverse drug events identified by screening electronic health records. J Patient Saf. 2010;6(2):91–6. Epub 2010/06/01. 10.1097/PTS.0b013e3181dcae06 .
    1. Medicines Management G. ADRE—THE ADVERSE DRUG REACTION PROFILE Swansea: Swansea University; [Accessed 7 April 2019].
    1. Jordan S, Banner T, Gabe-Walters M, Mikhail JM, Round J, Snelgrove S, et al. Nurse-led medicines’ monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines. BMJ Open. 2018;8(9):e023377 Epub 2018/10/01. 10.1136/bmjopen-2018-023377 .
    1. Jordan S, Logan PA, Panes G, Vaismoradi M, Hughes D. Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles. Pharmacy (Basel). 2018;6(3). Epub 2018/09/21. 10.3390/pharmacy6030102 .
    1. Jordan S, Gabe M, Newson L, Snelgrove S, Panes G, Picek A, et al. Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring. Scientific World Journal. 2014:843621 Epub 2014/04/08. 10.1155/2014/843621 .
    1. Jordan S, Gabe-Walters ME, Watkins A, Humphreys I, Newson L, Snelgrove S, et al. Nurse-Led Medicines’ Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped Wedge Cluster Randomised Trial. PLoS One. 2015;10(10):e0140203 Epub 2015/10/16. 10.1371/journal.pone.0140203 .
    1. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. Bmj. 2015;350:h1258 Epub 2015/03/21. 10.1136/bmj.h1258 .
    1. Willis CD, Saul J, Bevan H, Scheirer MA, Best A, Greenhalgh T, et al. Sustaining organizational culture change in health systems. J Health Organ Manag. 2016;30(1):2–30. Epub 2016/03/12. 10.1108/JHOM-07-2014-0117 .
    1. Information Commissioners Office. Anonymisation: managing data protection risk code of practice Cheshire: ICO; 2012 [Accessed 07 April 2019]. .
    1. Glaser B, Strauss A. The Discovery of Grounded Theory. Chicago: Aldine; 1967.
    1. Siafis S, Papazisis G. Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic study. British journal of clinical pharmacology. 2018;84(10):2405–14. Epub 2018/06/29. 10.1111/bcp.13699 .
    1. Ble A, Hughes PM, Delgado J, Masoli JA, Bowman K, Zirk-Sadowski J, et al. Safety and Effectiveness of Statins for Prevention of Recurrent Myocardial Infarction in 12 156 Typical Older Patients: A Quasi-Experimental Study. J Gerontol A Biol Sci Med Sci. 2017;72(2):243–50. Epub 2016/05/06. 10.1093/gerona/glw082 .
    1. Alldred DP, Kennedy MC, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. The Cochrane database of systematic reviews. 2016;2:CD009095 Epub 2016/02/13. 10.1002/14651858.CD009095.pub3 .
    1. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. British journal of clinical pharmacology. 2016;82(3):583–623. Epub 2016/04/15. 10.1111/bcp.12975 .
    1. Johansson T, Abuzahra ME, Keller S, Mann E, Faller B, Sommerauer C, et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. British journal of clinical pharmacology. 2016;82(2):532–48. Epub 2016/04/10. 10.1111/bcp.12959 .
    1. Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. The Cochrane database of systematic reviews. 2018;9:CD008165 Epub 2018/09/04. 10.1002/14651858.CD008165.pub4 .
    1. Vancampfort D, Firth J, Correll CU, Solmi M, Siskind D, De Hert M, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019;18(1):53–66. Epub 2019/01/03. 10.1002/wps.20614 .
    1. Ballard C, Orrell M, Sun Y, Moniz-Cook E, Stafford J, Whitaker R, et al. Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD-a factorial cluster randomised controlled trial. Int J Geriatr Psychiatry. 2016. Epub 2016/09/20. 10.1002/gps.4572 .
    1. Desveaux L, Saragosa M, Rogers J, Bevan L, Loshak H, Moser A, et al. Improving the appropriateness of antipsychotic prescribing in nursing homes: a mixed-methods process evaluation of an academic detailing intervention. Implement Sci. 2017;12(1):71 Epub 2017/05/28. 10.1186/s13012-017-0602-z .
    1. Mestres Gonzalvo C, Milosevic V, van Oijen BPC, de Wit H, Hurkens K, Mulder WJ, et al. The use of an electronic clinical rule to discontinue chronically used benzodiazepines and related Z drugs. Eur J Clin Pharmacol. 2018;74(2):227–31. Epub 2017/11/12. 10.1007/s00228-017-2369-1 .
    1. Westbury JL, Gee P, Ling T, Brown DT, Franks KH, Bindoff I, et al. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities. Med J Aust. 2018;208(9):398–403. Epub 2018/05/12. .
    1. Kua CH, Mak VSL, Huey Lee SW. Health Outcomes of Deprescribing Interventions Among Older Residents in Nursing Homes: A Systematic Review and Meta-analysis. J Am Med Dir Assoc. 2019;20(3):362–72 e11. Epub 2018/12/26. 10.1016/j.jamda.2018.10.026 .
    1. Sino CG, Bouvy ML, Jansen PA, Schop IM, Egberts TC, Schuurmans MJ. Signs and symptoms indicative of potential adverse drug reactions in homecare patients. J Am Med Dir Assoc. 2013;14(12):920–5. Epub 2013/11/30. 10.1016/j.jamda.2013.09.014 .
    1. Shafiee Hanjani L, Long D, Peel NM, Peeters G, Freeman CR, Hubbard RE. Interventions to Optimise Prescribing in Older People with Dementia: A Systematic Review. Drugs Aging. 2019;36(3):247–67. Epub 2018/12/20. 10.1007/s40266-018-0620-9 .
    1. Pevnick JM, Shane R, Schnipper JL. The problem with medication reconciliation. BMJ Qual Saf. 2016;25(9):726–30. Epub 2016/01/23. 10.1136/bmjqs-2015-004734 .
    1. Jennings E, Gallagher P, O’Mahony D. Detection and prevention of adverse drug reactions in multi-morbid older patients. Age Ageing. 2019;48(1):10–3. Epub 2018/10/10. 10.1093/ageing/afy157 .
    1. Lewis G, Wessely S. The epidemiology of fatigue: more questions than answers. Journal of epidemiology and community health. 1992;46(2):92–7. 10.1136/jech.46.2.92 .
    1. Goodman C, Davies SL, Gordon AL, Dening T, Gage H, Meyer J, et al. Optimal NHS service delivery to care homes: a realist evaluation of the features and mechanisms that support effective working for the continuing care of older people in residential settings. Health Services and Delivery Research. Southampton (UK) 2017.
    1. Drennan VM, Grant RL, Harris R. Trends over time in prescribing by English primary care nurses: a secondary analysis of a national prescription database. BMC Health Serv Res. 2014;14:54 Epub 2014/02/07. 10.1186/1472-6963-14-54 .
    1. Hart JT. The inverse care law. Lancet (London, England). 1971;1(7696):405–12. Epub 1971/02/27. 10.1016/s0140-6736(71)92410-x .
    1. Payne RA, Abel GA, Guthrie B, Mercer SW. The effect of physical multimorbidity, mental health conditions and socioeconomic deprivation on unplanned admissions to hospital: a retrospective cohort study. CMAJ. 2013;185(5):E221–8. Epub 2013/02/21. 10.1503/cmaj.121349 .
    1. Formica D, Sultana J, Cutroneo PM, Lucchesi S, Angelica R, Crisafulli S, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018;17(7):681–95. Epub 2018/06/29. 10.1080/14740338.2018.1491547 .
    1. McGrattan M, Ryan C, Barry HE, Hughes CM. Interventions to Improve Medicines Management for People with Dementia: A Systematic Review. Drugs Aging. 2017;34(12):907–16. Epub 2017/11/28. 10.1007/s40266-017-0505-3 .
    1. Sheikh A, Cornford T, Barber N, Avery A, Takian A, Lichtner V, et al. Implementation and adoption of nationwide electronic health records in secondary care in England: final qualitative results from prospective national evaluation in "early adopter" hospitals. BMJ. 2011;343:d6054 Epub 2011/10/19. 10.1136/bmj.d6054 .
    1. Jeffries M, Phipps D, Howard RL, Avery A, Rodgers S, Ashcroft D. Understanding the implementation and adoption of an information technology intervention to support medicine optimisation in primary care: qualitative study using strong structuration theory. BMJ Open. 2017;7(5):e014810 Epub 2017/05/13. 10.1136/bmjopen-2016-014810 .
    1. Lyell D, Magrabi F, Raban MZ, Pont LG, Baysari MT, Day RO, et al. Automation bias in electronic prescribing. BMC Med Inform Decis Mak. 2017;17(1):28 Epub 2017/03/18. 10.1186/s12911-017-0425-5 .
    1. Arndt BG, Beasley JW, Watkinson MD, Temte JL, Tuan WJ, Sinsky CA, et al. Tethered to the EHR: Primary Care Physician Workload Assessment Using EHR Event Log Data and Time-Motion Observations. Ann Fam Med. 2017;15(5):419–26. Epub 2017/09/13. 10.1370/afm.2121 .
    1. Shanafelt TD, Dyrbye LN, Sinsky C, Hasan O, Satele D, Sloan J, et al. Relationship Between Clerical Burden and Characteristics of the Electronic Environment With Physician Burnout and Professional Satisfaction. Mayo Clin Proc. 2016;91(7):836–48. Epub 2016/06/18. 10.1016/j.mayocp.2016.05.007 .
    1. Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M, et al. Electronic Systems for Patients to Report and Manage Side Effects of Cancer Treatment: Systematic Review. J Med Internet Res. 2019;21(1):e10875 Epub 2019/01/27. 10.2196/10875 .
    1. Jordan S, Kyriacos U. Medicines’ management: a public health problem on nursing’s agenda. J Nurs Manag. 2014;22(3):271–5. Epub 2014/04/24. 10.1111/jonm.12238 .
    1. Keijsers CJ, Leendertse AJ, Faber A, Brouwers JR, de Wildt DJ, Jansen PA. Pharmacists’ and general practitioners’ pharmacology knowledge and pharmacotherapy skills. J Clin Pharmacol. 2015;55(8):936–43. Epub 2015/03/27. 10.1002/jcph.500 .
    1. Schnipper JL, Mixon A, Stein J, Wetterneck TB, Kaboli PJ, Mueller S, et al. Effects of a multifaceted medication reconciliation quality improvement intervention on patient safety: final results of the MARQUIS study. BMJ Qual Saf. 2018;27(12):954–64. Epub 2018/08/22. 10.1136/bmjqs-2018-008233 .
    1. Sackett DL HR, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine, Second edition Boston MA: Little, Brown & Co; 1991.
    1. Vaganay A. Outcome Reporting Bias in Government-Sponsored Policy Evaluations: A Qualitative Content Analysis of 13 Studies. PLoS One. 2016;11(9):e0163702 Epub 2016/10/01. 10.1371/journal.pone.0163702 .
    1. Ellwood A, Airlie J, Cicero R, Cundill B, Ellard DR, Farrin A, et al. Recruiting care homes to a randomised controlled trial. Trials. 2018;19(1):535 Epub 2018/10/05. 10.1186/s13063-018-2915-x .
    1. Mitchell JC. Case and Situation Analysis. The Sociological Review. 1983;31(2):187–211. 10.1111/j.1467-954X.1983.tb00387.x
    1. Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21–37. Epub 2007/12/22. 10.2165/00002018-200831010-00003 .
    1. Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11–22. Epub 2016/02/03. 10.1177/2042098615615472 .
    1. Centre UM. The use of the WHO_UMC system for standardised case causality assessment Sweden: UMC; 2018 [Accessed 5 March 2019]. .
    1. Mouton JP, Mehta U, Rossiter DP, Maartens G, Cohen K. Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system. PLoS One. 2017;12(2):e0172830 Epub 2017/02/25. 10.1371/journal.pone.0172830 .
    1. Willson A. The problem with eliminating ‘low-value care’. BMJ Qual Saf. 2015;24(10):611–4. Epub 2015/07/15. 10.1136/bmjqs-2015-004518 .
    1. May CR, Mair F, Finch T, MacFarlane A, Dowrick C, Treweek S, et al. Development of a theory of implementation and integration: Normalization Process Theory. Implement Sci. 2009;4:29 Epub 2009/05/23. 10.1186/1748-5908-4-29 .
    1. Robinson J. Research for whom? The politics of research dissemination and application In: Buckeldee J and McMahon R, editor. The Research Experience in Nursing London: Chapman Hall; 1994. p. 165–88.
    1. Gao L, Maidment I, Matthews FE, Robinson L, Brayne C, Medical Research Council Cognitive F, et al. Medication usage change in older people (65+) in England over 20 years: findings from CFAS I and CFAS II. Age Ageing. 2018;47(2):220–5. Epub 2017/10/17. 10.1093/ageing/afx158 .
    1. Wu TY, Jen MH, Bottle A, Molokhia M, Aylin P, Bell D, et al. Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009. Journal of the Royal Society of Medicine. 2010;103(6):239–50. Epub 2010/06/02. 10.1258/jrsm.2010.100113 .
    1. Office of National Statistics. Health state life expectancies by national deprivation deciles, England and Wales: 2014 to 2017. 2018 [Accessed 07 April 2019].
    1. World Health Organisation. Medication without harm 2017 [Accessed 07 April 2019]. .
    1. Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny MP, Sheikh A. Medication Without Harm: WHO’s Third Global Patient Safety Challenge. Lancet (London, England). 2017;389(10080):1680–1. Epub 2017/05/04. 10.1016/s0140-6736(17)31047-4 .
    1. Curtis K, Fulton E, Brown K. Factors influencing application of behavioural science evidence by public health decision-makers and practitioners, and implications for practice. Prev Med Rep. 2018;12:106–15. Epub 2018/09/21. 10.1016/j.pmedr.2018.08.012 .
    1. National Assembly for Wales (NAfW) H, Social Care and Sport Committee,. Use of Antipsychotic medication in care homes. Cardiff Bay: National Assembly, Wales; 2018 [Accessed 21 July 2018]. .

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다